|
Laxman Pai, Opalesque Asia: Nearly 9 out of 10 (87%) healthtech venture capital investors said generative AI solutions have influenced their investment strategies, said a study.
The GSR Ventures survey revealed that nearly two-thirds (62.5%) of investors expect to make the same number or more tech investments for the remainder of 2023 compared to 2022.
"Digital health investors say generative AI, oncology care, and the challenges posed by clinician shortages are transforming their startup funding strategies and investment outlooks for the healthcare industry," said the report.
Most investor valuation expectations for seed stage, Series A, and Series B companies decreased by 20% or more compared to 2022 - with the vast majority expecting lower valuations to continue for the remainder of 2023.
According to the survey, the oncology specialty holds the most promise for startups, according to 55% of investors, followed by cardiovascular care (37.5%). Nearly one-third (31%) of investors say ophthalmology offers the least opportunity.
Half of investors (50%) said the provider shortage and burnout crisis present the biggest problem-solving opportunity for startup companies, followed by changing reimbursement models (26.3%).
"Digital health investors are a small, but highly influential community driving the innovations that will transform how care is delivered and managed, and blockbuster new therapies that are discovered," said Sunny Kum...................... To view our full article Click here
|
RSS
